XORTX Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Jan '22 Jan 1, 2022	2021 - 2017
Selling, General & Admin	1.83	2.19	2.28	1.93	1.22	Upgrade
Research & Development	0.57	0.18	2.42	6.76	0.68	Upgrade
Amortization of Goodwill & Intangibles	0.03	0.03	0.07	0.02	0.01	Upgrade
Operating Expenses	2.54	2.62	4.96	9.24	2.31	Upgrade
Operating Income	-2.54	-2.62	-4.96	-9.24	-2.31	Upgrade
Interest Expense	-	-	-	-	-0	Upgrade
Interest & Investment Income	0.04	0.12	0.25	0.1	-	Upgrade
Currency Exchange Gain (Loss)	-0	-0.07	-0.01	-0	-0.01	Upgrade
Other Non Operating Income (Expenses)	-0.15	-0.75	2.55	1.42	0.75	Upgrade
EBT Excluding Unusual Items	-2.65	-3.31	-2.16	-7.72	-1.58	Upgrade
Asset Writedown	-0	-	-	-	-	Upgrade
Pretax Income	-2.66	-3.31	-2.16	-7.72	-1.58	Upgrade
Net Income	-2.66	-3.31	-2.16	-7.72	-1.58	Upgrade
Net Income to Common	-2.66	-3.31	-2.16	-7.72	-1.58	Upgrade
Shares Outstanding (Basic)	5	3	2	1	1	Upgrade
Shares Outstanding (Diluted)	5	3	2	1	1	Upgrade
Shares Change (YoY)	64.48%	45.25%	33.91%	35.25%	47.77%	Upgrade
EPS (Basic)	-0.56	-1.15	-1.09	-5.22	-1.44	Upgrade
EPS (Diluted)	-0.56	-1.15	-1.09	-5.22	-1.44	Upgrade
Free Cash Flow	-2.77	-3.68	-6.59	-8.19	-4.8	Upgrade
Free Cash Flow Per Share	-0.58	-1.28	-3.32	-5.53	-4.39	Upgrade
EBITDA	-2.43	-2.58	-4.88	-9.22	-2.3	Upgrade
D&A For EBITDA	0.11	0.04	0.07	0.02	0.01	Upgrade
EBIT	-2.54	-2.62	-4.96	-9.24	-2.31	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.